3a:{"drug_id":928397,"title":"Esomeprazole Sodium","ind":"FDA-Labeled Indications

Erosive esophagitis - Gastroesophageal reflux disease
Recurrent gastrointestinal bleeding, following therapeutic endoscopy; Prophylaxis

","adult":"

Erosive esophagitis - Gastroesophageal reflux disease
- 20 or 40 mg once daily by IV injection (no less than 3 min) once daily or IV infusion over 10 to 30 min
Recurrent gastrointestinal bleeding, following therapeutic endoscopy; Prophylaxis
- 80 mg IV over 30 minutes, and then 8 mg/hr continuous IV infusion for a total of 72 hours; followed with oral acid-suppressive therapy

","ped":"Erosive esophagitis - Gastroesophageal reflux disease

1 month to less than 1 year of age, 0.5 mg/kg IV infusion over 10 to 30 min once daily
1 to 17 years of age, 10 mg (body weight less than 55 kg) or 20 mg (body weight 55 kg or greater) IV infusion over 10 to 30 min once daily

","side":"Common

Dermatologic:Injection site reaction (1.7% to 4.3%)
Gastrointestinal:Abdominal pain (5.8%), Constipation (2.5%), Diarrhea (3.9%), Flatulence (10.3%), Indigestion (6.4%), Nausea (6.4%), Xerostomia (3.9%)
Neurologic:Dizziness (1.1% to 2.5%), Headache (10.9%)

Serious

Dermatologic:Erythema multiforme (rare), Stevens-Johnson syndrome (rare), Toxic epidermal necrolysis (rare)
Gastrointestinal:Clostridium difficile diarrhea
Musculoskeletal:Fracture of bone, Rhabdomyolysis
Renal:Interstitial nephritis, acute

","prgnancy":"Esomeprazole: C (FDA)
","intermajer":"

Atazanavir (theoretical)
Bosutinib (theoretical)
Cilostazol (theoretical)
Citalopram (theoretical)
Clopidogrel (established)
Dabrafenib (theoretical)
Dasatinib (theoretical)
Erlotinib (theoretical)
Eslicarbazepine Acetate (theoretical)
Gefitinib (theoretical)
Ketoconazole (theoretical)
Ledipasvir (theoretical)
Methotrexate (probable)
Mycophenolate Mofetil (theoretical)
Nelfinavir (probable)
Nilotinib (theoretical)
Pazopanib (established)
Posaconazole (established)
Saquinavir (theoretical)
Tacrolimus (probable)
Thiopental (established)
Vismodegib (theoretical)

","clinical":"

Advise patient to report diarrhea that does not improve, especially with persistent watery stools, fever, and abdominal pain.
Drug may cause injection site reactions, dry mouth, dizziness, vertigo, headaches, abdominal pain, flatulence, nausea, constipation, diarrhea, or pruritus.
Instruct patient to immediately report signs/symptoms of hypomagnesemia, including palpitations, arrhythmias, seizures, dizziness, or tetany.

","admin":"Intravenous

(20 mg or 40 mg vial) reconstitute vials with 5 mL of NS; use within 12 hours after reconstitution; refrigeration is not required
(IV injection, adults only) give over at least 3 minutes
(IV infusion) further dilute with NS, LR, or D5W, store at room temperature; admixtures with NS or LR, administer within 12 hours; admixtures with D5W, administer within 6 hours
(intermittent IV infusion) further dilute dose to final volume of 50 mL with NS, LR or D5W; infuse over 10 to 30 minutes
(loading dose) further dilute 80 mg dose in 100 mL NS; administer over 30 minutes
(continuous infusion) reconstitute two 40-mg vials, then further dilute in 100 mL NS; administer at 8 mg/hr for 71.5 hours
do NOT administer concomitantly with any other medications through the same IV site or tubing (flush IV line with NS, D5W, or lactated Ringer before and after administration)

","interminor":"

Cranberry (probable)
Levothyroxine (probable)
Risedronate (established)
Warfarin (probable)

","contra":"

Rilpivirine (theoretical)","clas":"Gastric Acid Secretion Inhibitor","mode":"Esomeprazole sodium, a proton pump inhibitor, inhibits the terminal stage in acid production by binding specifically to H(+)/K(+)-ATPase in gastric parietal cells, thereby suppressing gastric acid secretion.
"}

Esome (Esomeprazole Sodium - Powder for solution for injection or infusion 40mg/ Vial) – Full Drug Info.

SCIENTIFIC NAME

INDICATIONS

CLASSIFICATION

MECHANISM OF ACTION

CLINICAL USE

ADULT DOSE

PEDIATRIC DOSE

ADMINISTRATION

CONTRAINDICATIONS

SIDE EFFECTS

PREGNANCY

MAJOR INTERACTIONS

MINOR INTERACTIONS